- Mithramycin A
| 10058-F4C-Myc-Max dimerization inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.03%
- COA (Certificate Of Analysis)
- HPLC
- MS (Mass Spectrometry)(Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Description | 10058-F4 is a small-molecule and cell-permeable inhibitor of c-Myc-Max dimerization. | |||||
| Targets | c-Myc-Max dimerization | |||||
| IC50 | ||||||
| Cell experiment [1]: | |
Cell lines | HL-60, U937 and NB-4 cells |
Preparation method | The solubility of this compound in DMSO is > 12.5 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition | 0, 30, 60, 100 and 150 μM; 72 hrs |
Applications | All AML cell lines (HL-60, U937 and NB-4) were sensitive to 10058-F4 in a dose-dependent manner. At the dose of 100 μM, 10058-F4 significantly induced apoptosis of AML cell after the 72-hr treatment. In addition, 10058-F4 decreased levels of c-Myc proteins in all AML cell lines. |
| Animal experiment [2]: | |
Animal models | SCID mice bearing DU145 or PC-3 human prostate cancer xenografts |
Dosage form | 20 or 30 mg/kg; i.v.; q.d., 5 days per week, for 2 weeks |
Applications | In mice bearing PC-3 xenografts, intravenous treatment with 20 or 30 mg/kg 10058-F4 resulted in the maximum mean %TC values of 72.3 and 72.9%, respectively. Similarly, in mice bearing DU145 xenografts, 30 mg/kg 10058-F4 resulted in a maximum mean %TC value of 85%. 10058-F4 showed lack of effect in both models. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Huang MJ, Cheng YC, Liu CR, Lin SF, Liu H. E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Experimental Hematology. 2006; 34: 1480–1489. [2]. Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. | |
10058-F4 Dilution Calculator
calculate
10058-F4 Molarity Calculator
calculate
| Cas No. | 403811-55-2 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one | ||
| Canonical SMILES | CCC1=CC=C(C=C1)C=C2C(=O)NC(=S)S2 | ||
| Formula | C12H11NOS2 | M.Wt | 249.35 |
| Solubility | ≥24.9mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
10058-F4 is a novel small-molecule inhibitor of c-Myc. 10058-F4 prevented the binding of c-Myc/Max dimers to its DNA targets, inhibited leukemic proliferation, and induced apoptosis through mitochondrial pathway, such as downregulation of Bcl-2, upregulation of Bax and release of cytoplasmic cytochrome C. [1]
10058-F4 blocks the C-MYC/Max heterodimerization which is required for c-Myc activity as a transcription factor. 10058-F4 efficiently inhibits the induction of PGC-1β mRNA by both HRG and IGF-1 and also abolishes the induction of PGC-1β protein levels by HRG and IGF-1, confirming that the induction of PGC-1b protein by these growth factors is a transcriptional event requiring C-MYC activity.[2] 10058-F4 acts not only to block c-Myc function through the mechanism of c-Myc/Max heterodimer dissociation, but it also resulted in decreased c-Myc mRNA levels (65%, n = 3) in lymphoma cells.[3]
References:[1] Huang MJ, Cheng YC, Liu CR, Lin SF, Liu H. E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Experimental Hematology. 2006; 34: 1480–1489.[2] Ching-yi Chang, Dmitri Kazmin, Jeff S. Jasper, Rebecca Kunder, William J. Zuercher, Donald P. McDonnell. The Metabolic Regulator ERRα, a Downstream Target of HER2/IGF-1R, as a Therapeutic Target in Breast Cancer. Cancer Cell. 18 October 2011. 20(4): 500-510.[3] Ilsa Gomez-Curet, R. Serene Perkins, Ryan Bennett, Katherine L. Feidler, Stephen P. Dunn, Leslie J. Krueger. c-Myc inhibition negatively impacts lymphoma growth. Journal of Pediatric Surgery. January 2006. 41(1): 207-211.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
总局关于发布医用磁共振成像系统临床评价等4项医疗器械注册技术审查指导原则的通告（2017年第6号）
2017年01月16日发布http://www.sfda.gov.cn/WS01/CL0087/168596.html
为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家食品药品监督管理总局组织制定了《医用磁共振成像系统临床评价技术审查指导原则》《口腔颌面锥形束计算机体层摄影设备注册技术审查指导原则》《体外除颤产品注册技术审查指导原则》《光固化机注册技术审查指导原则》（见附件），现予发布。
特此通告。
附件：1.医用磁共振成像系统临床评价技术审查指导原则
2.口腔颌面锥形束计算机体层摄影设备注册技术审查指导原则
3.体外除颤产品注册技术审查指导原则
4.光固化机注册技术审查指导原则
食品药品监管总局
2017年1月10日
2017年第6号通告附件1.docx
2017年第6号通告附件2.docx
2017年第6号通告附件3.doc
2017年第6号通告附件4.docx
图1 光声成像工程 (a)光声信号激发与探测；(b)光声成像实现过程示意图
光声成像过程可以分为三个部分：信号的产生、信号的接收和信号处理及图像重建（见图1）。由于脉冲激光器具有光声转换效率高的优点，因此通常被作为光声成像研究中产生信号的激励源。脉冲激光器发出的激光束照射在待研究组织样品上，由于组织样品的吸收效应，在样品内部形成了与组织光学参数相关的能量沉积分布。由于激光脉宽很窄（ns）吸收的能量不能在短时间内释放，导致瞬间温度变化，从而通过热弹机制转化为热膨胀。周期性热流使周围的介质热胀冷缩而激发超声波，由于这种超声波信号的特殊产生机理，为了区别于其它的超声信号，通常称为光声信号。利用超声探测器接收光声信号并对采集到的信号进行适当地处理和采用相应的图像重建算法，就能够得到样品内部光能量沉积的分布。当保证入射光的均匀性的前提下，光声重建图像与吸收分布具有一一对应的关系。向左转|向右转
光系统设计难各种光系统都各自特点所像质优化重点全致 没像数或者物理领域种著名课题 希望能帮
请问成像系统工作站请问那家的产品做得比较好以及专业一些呢？
实验室新组建，想咨询一下Camag薄层色谱成像系统的价格及一套显微成像的设备清单与价格。显微成像主要用于中药材的显微鉴别
显微镜是OlympusDP71，弄比例尺的时候出来个“衸”，这是什么鬼啊？如何换算成微米？测量的那个选项我选的是10微米，也只有那个选项可以点。然后倍数选择200，然后他就出来这个200衸，选100倍数是500衸，400倍是200也衸，但长度是200的两倍，**各位大神帮帮忙，要怎样才能换成微米？另外1衸是多少微米？
